AI Stock Monitor
AMGN - Amgen
Amgen is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Biotechnology · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
60
/100
Price History
AMGN chart
AI-Assisted Chart Analysis
Amgen technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 63, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 326.31. A break below 272.98 invalidates the near-term support setup.
The first resistance/watch zone is 439.33. A confirmed break above 439.33 supports continuation.
Annualized realized volatility is +55.3%. Maximum lookback drawdown is -24.5%, from a high-water mark of 287.29 to 216.93.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported AMGN at 393.16 USD; the latest daily move rose +1.95%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +1.95% daily move is current market context for Amgen.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current evidence-grounded AI read is bullish.
- Evidence: Amgen's fundamental strength is supported by its dividend profile and ongoing pipeline updates, such as those for MariTide and IMDELLTRA, which were recently reaffirmed at the Morgan Stanley conference.
- Uncertainty: However, the stock remains susceptible to 'guilt by association' volatility, as seen in the recent price drop linked to a competitor's failed trial, and faces specific legal risks from ongoing patent litigation.
- Watch: The expansion of the Veeva partnership is a positive indicator of internal operational discipline, which could help mitigate margin pressure.
Key Risks
- Legal and regulatory challenges, such as the Bristol Myers lawsuit, could delay or block the launch of key biosimilar products, directly impacting future revenue streams.
- Market volatility driven by external competitor trial failures creates unpredictable price swings that may not reflect Amgen's internal fundamentals.
- Pipeline execution risk remains high; any negative data readouts for key assets like MariTide would significantly impair the growth narrative and valuation.
Upcoming Catalysts
- Clinical trial updates for MariTide and other late-stage pipeline assets will be the primary drivers of long-term valuation and investor sentiment.
- Resolution of the Bristol Myers Opdivo biosimilar litigation would remove a key overhang on the biosimilar business unit.
- Future earnings reports and management commentary on capital allocation, particularly regarding dividend growth and R&D spending, will confirm the company's ability to navigate competitive pressures.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedStock Market Today: Dow Up, Nasdaq Roars To Record As Micron Does This; AMD Hits New High · Published 2026-09-22 00:01:43Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionVeeva Expands Amgen Partnership With Global Vault CRM Rollout Plan - Zacks Investment Research · Published 2026-09-22 00:01:43Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedVeeva Expands Amgen Partnership With Global Vault CRM Rollout Plan - Yahoo Finance · Published 2026-09-22 00:01:43Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedVeeva Expands Amgen Partnership With Global Vault CRM Rollout Plan · Published 2026-09-22 00:01:43Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedBiotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate · Published 2026-09-22 00:01:43Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.